APA (7th ed.) Citation

RK, Y., AQ, N., SW, S., SS, A., WA, N., SA, M., . . . MS, S. (2026). CRISPR-Cas technologies in neurodegenerative disorders: Mechanistic insights, therapeutic potential, and translational challenges. Frontiers in neurology, 16, 1737468. https://doi.org/10.3389/fneur.2025.1737468

Chicago Style (17th ed.) Citation

RK, Yashooa, Nabi AQ, Smail SW, Azeez SS, Nooh WA, Mustafa SA, Al-Farha AA, Capitanio N, and Shekha MS. "CRISPR-Cas Technologies in Neurodegenerative Disorders: Mechanistic Insights, Therapeutic Potential, and Translational Challenges." Frontiers in Neurology 16 (2026): 1737468. https://doi.org/10.3389/fneur.2025.1737468.

MLA (9th ed.) Citation

RK, Yashooa, et al. "CRISPR-Cas Technologies in Neurodegenerative Disorders: Mechanistic Insights, Therapeutic Potential, and Translational Challenges." Frontiers in Neurology, vol. 16, 2026, p. 1737468, https://doi.org/10.3389/fneur.2025.1737468.